271. Ankylosing spondylitis
531 clinical trials,   343 drugs   (DrugBank: 66 drugs),   41 drug target genes,   141 drug target pathways

Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00558506
(ClinicalTrials.gov)
January 200814/11/2007Pilot Open Label Clinical Trial With Abatacept in Ankylosing SpondylitisPilot Open Label Clinical Trial With Abatacept in Ankylosing SpondylitisAnkylosing SpondylitisDrug: abataceptCharite University, Berlin, GermanyBristol-Myers SquibbRecruiting18 Years65 YearsBoth30Phase 2Germany
2EUCTR2007-002967-28-DE
(EUCTR)
19/10/200724/08/2007Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis - ABATACEPT-AS-01Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis - ABATACEPT-AS-01 T cell responses have been demonstrated against proteoglycan (an important cartilage protein) in human arthritides including ankylosing spondylitis. We suggest that a chronic, probably T cell mediated, immune response against cartilage is relevant in the pathogenesis of AS.Based on the above described findings about the role of T-cells in ankylosing spondylitis we assume that Abatacept has the potential to be an effective drug for treating ankylosing spondylitis. Trade Name: not applicable
Product Name: Orencia
Product Code: BMS-188667
INN or Proposed INN: Abatacept
Other descriptive name: CTLA4Ig
Charité University MedicineNULLNot RecruitingFemale: yes
Male: yes
30Germany